-+ 0.00%
-+ 0.00%
-+ 0.00%
iSpecimen Q3 net loss narrows 21% to $2.2 million; revenue more than doubles to $244,000
Share
Listen to the news
iSpecimen Q3 net loss narrows 21% to $2.2 million; revenue more than doubles to $244,000
  • iSpecimen’s third-quarter 2026 net loss narrowed 21% year over year to approximately $2.2 million.
  • Revenue more than doubled to approximately $244,000, driven mainly by higher customer orders and procurement.
  • Cost of revenue fell 55% to approximately $91,000, while specimens delivered more than doubled to 752.
  • Since 2020, 21 biospecimen orders were fulfilled across nine government and government-affiliated organizations, including the CDC.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iSpecimen Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611191605NEWSFILECNPR____20261119_324745_1) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending